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 Letter to the Editor: Comparison of Two Coarse Fractionated Radiation Protocols for 
the Management of Canine Pituitary Macrotumor: an Observational Study of 24 Dogs, 
Marcinowska et al., doi: 10.1111/vru.12270 
 
 
Dear Editor,  
With interest I have read the article by Marcinowska and colleagues titled “Comparison of two 
coarse fractionated radiation protocols for the management of canine pituitary macrotumor: an 
observational study of 24 dogs”. In this publication, the authors report the outcome of patients 
with pituitary macrotumors treated with a protocol consisting of either 10x3.8 Gy or 
1x5Gy+4x8.25 Gy. I have to raise a major concern regarding the latter of the radiation 
protocols used: under the described technical conditions, the dose per fraction is too high and 
the justification with the given BED calculation does not adequately impress this risk upon the 
reader. While I understand that for groups without daily access to treatment machines and/or 
the need of manual calculation of the treatment fields, a reduction in fraction number and 
conformity have to be made, the general basic principles of dose and fractionation should still 
be considered.  
For the protocol of 1x5Gy+4x8.25Gy used herein, my criticism is as follows: the authors state 
a BED of 138.5Gy, and they compare this number to other published protocols.1-3 A basic 
explanation of the “BED” is attempted. While the authors set the BED of 138.5Gy in relation 
to applied protocol fractionation schedules in older publications, no quantification of the 
consequences (e.g. endpoint; “isoeffect”) in terms of normal tissue complication probability 
(NTCP) of such a protocol is given, rendering the BED to a purely quantitative number. This 
is one of the known disadvantages of the BED-concept as a measure of treatment intensity: 
the derived number is numerically much greater than any “real” prescribeable radiation dose 
and therefore is not easy to relate to everyday clinical practice. 
By using the simpler concept (mathematically and biologically equivalent) of EQD2 4, 
treatment schedules that have differing doses per fraction can be compared with much more 
relatable derived doses. These doses can further readily be compared to toxicity data 
published for tissues and endpoints in human medicine. Hence a fast, albeit rough comparison 
for organ tolerance can be made for a protocol, if an extensive NTCP-calculation cannot be 
made. Such a comparison needs the generous assumption that canine neuronal tissue is 
equally sensitive to ionizing radiation as human neuronal tissue, which is a limitation of this 
approach. However the impact of the comparison of EQD2 values communicates more 
effectively the potential for toxicity than comparison of BED values.  
 
With the manual calculation of the fields and the portal sizes used in the publication of 
Marcinowska et al., volumes of about 20-40 cm3 can be derived as “treated volume” (e.g. the 
volume enclosed by an isodose surface, selected and specified as being appropriate to achieve 
the purpose of treatment)5, 6. Regular canine brain volumes range in the magnitude of 82 +/- 
19cm3,7 in consequence, this dose was applied to at least an approximate 1/3 to 1/2 of the total 
brain volume in most of the cases. 
 
Tabulated below the BED and EQD2 of the protocols mentioned in the publication  
 10x3.8Gy 1x5Gy+4x8.25Gy 5+7+8+9 +9Gy1  12x4Gy3 16x3Gy2  20x2.5Gy8 
Total dose 38Gy 38Gy 38Gy 48Gy 48Gy 50Gy 
BED (α/β=3) 86.1 138.5 137.9 110.4 96 91.6 
EQD2 (α/β=3) 51.7 82.3 82.2 67.2 57.6 55 
 
If now we compare these numbers (EQD2) to the tabulated numbers of the old, but still 
frequently used reference for TD5/5 and TD50/5,9 
 
 TD5/5* Volume TD50/5 Volume  
Volume 1/3 2/3 3/3 1/3 2/3 3/3 Endpoint 
Brain 60 50 45 75 65 60 Necrosis 
Chiasma No partial volume 50 No partial volume 65 Blindness 
* dosis tolerata (tolerance dose), risk for late toxicity 5% (TD5/5) or 50% (TD50/5) at 5 years 
 
these numbers lead to the – admittedly very rough – conclusion, that the risk of inducing brain 
necrosis with the 1x5Gy+4x8.25Gy protocol (EQD2 of 82.3) could be substantial. 
As suggested in the QUANTEC Report, Emami’s estimate for fractionated partial brain 
irradiation (TD5/5 for 1/3 of the brain volume, 60Gy) may be overly conservative.10-12 More 
recent data suggest a TD5/5 (partial) of 72Gy, in 2Gy fractions, which confers to a BED of 
about 120Gy.10 This number, however, exceeds the tolerance for the optic chiasm11 and the 
brain stem,12 which are anatomically flanking the area of a pituitary tumor. Furthermore, 
given the very crude method of target delineation, treatment planning and delivery of 
radiotherapy (single-slice 2D MR planning and no position verification) in the study of 
Marcinowska et al., it is probably justified to assume a more conservative tolerance dose. In 
addition, as the brain is especially sensitive to fraction sizes >2Gy, severely hypofractionated 
regimes will probably be underestimated by EQD2 or BED calculations regarding possible 
late complications. 
 
While the authors mention the possibility of radiation injury caused by this protocol, not 
much emphasis is given to this “possibility” as the observed complications occurred very 
early rather than after the expected time delay of several months to years which is typical for 
late toxicity. Unfortunately, no evaluation for late toxicity is provided for this in this study, 
rendering the deaths of these patients futile. MRI and/or postmortem histopathology should 
have been included in at least a part of these patients.  
For this study, it must be assumed that the 1x5Gy+4x8.25Gy protocol carries a high risk for 
complications and that the incredibly early occurrence of clinical signs implicates a severe 
breach in radiobiological considerations of this protocol given the non-conformal, non-
verified dose delivery technique. In my personal view, using a protocol with a dose equivalent 
that exeeds advisable toxicity ranges should not be attempted without appropriate use of 
conformal techniques at the cost of sick patients. Canine pituitary macroadenoma is a disease 
that undoubtedly carries a very favorable prognosis if treated within the calculable risk.2, 7 For 
colleagues using radiation therapy, delivering the prescribed dose to a defined target, while 
maintaining dose within tolerance to normal tissues should remain the overarching principle 
of clinical practice. 
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